000131845 001__ 131845
000131845 005__ 20241125101159.0
000131845 0247_ $$2doi$$a10.3390/jcm12237243
000131845 0248_ $$2sideral$$a136998
000131845 037__ $$aART-2023-136998
000131845 041__ $$aeng
000131845 100__ $$aSancho-Saldaña, Agustín
000131845 245__ $$aSeroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study
000131845 260__ $$c2023
000131845 5060_ $$aAccess copy available to the general public$$fUnrestricted
000131845 5203_ $$aBackground: The EMCOVID project conducted a multi-centre cohort study to investigate the impact of COVID-19 on patients with Multiple Sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The study aimed to evaluate the seroprevalence and persistence of SARS-CoV-2 antibodies in MS patients enrolled in the EMCOVID database. The DMTs were used to manage MS by reducing relapses, lesion accumulation, and disability progression. However, concerns arose regarding the susceptibility of pwMS to COVID-19 due to potential interactions between SARS-CoV-2 and the immune system, as well as the immunomodulatory effects of DMTs. Methods: This prospective observational study utilized data from a Multiple Sclerosis and COVID-19 (EMCOVID-19) study. Demographic characteristics, MS history, laboratory data, SARS-CoV-2 serology, and symptoms of COVID-19 were extracted for pwMS receiving any type of DMT. The relationship between demographics, MS phenotype, DMTs, and COVID-19 was evaluated. The evolution of SARS-CoV-2 antibodies over a 6-month period was also assessed. Results: The study included 709 pwMS, with 376 patients providing samples at the 6-month follow-up visit. The seroprevalence of SARS-CoV-2 antibodies was higher among pwMS than the general population, with Interferon treatment being significantly associated with greater seroprevalence (16.9% vs. 8.4%; p 0.003). However, no other specific DMT showed a significant association with antibody presence. A total of 32 patients (8.5%) tested positive for IgG, IgM, or IgA antibodies against SARS-CoV-2 at baseline, but then tested negative at 6 months. Most of the pwMS in the cohort were asymptomatic for COVID-19 and, even among symptomatic cases, the prognosis was generally favourable. Conclusion: pwMS undergoing DMTs exhibited a higher seroprevalence of COVID-19 than the general population. Interferon treatment was associated with a higher seroprevalence, suggesting a more robust humoral response. This study provides valuable insights into the seroprevalence and persistence of SARS-CoV-2 antibodies in pwMS and contributes to our understanding of the impact of COVID-19 amongst this population.
000131845 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/COV20-00948
000131845 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000131845 590__ $$a3.0$$b2023
000131845 592__ $$a0.882$$b2023
000131845 591__ $$aMEDICINE, GENERAL & INTERNAL$$b59 / 329 = 0.179$$c2023$$dQ1$$eT1
000131845 593__ $$aMedicine (miscellaneous)$$c2023$$dQ1
000131845 594__ $$a5.7$$b2023
000131845 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000131845 700__ $$aGil-Sánchez, Anna
000131845 700__ $$aGonzález-Mingot, Cristina
000131845 700__ $$aPeralta, Silvia
000131845 700__ $$aSolana, Maria Jose
000131845 700__ $$aTorres, Pascual
000131845 700__ $$aJuanes, Alba
000131845 700__ $$aQuibus, Laura
000131845 700__ $$aRuiz, Emilio
000131845 700__ $$aSanpedro, Eduardo
000131845 700__ $$aQuirant-Sánchez, Bibiana
000131845 700__ $$aMartínez-Cáceres, Eva
000131845 700__ $$aRamo Tello, Cristina
000131845 700__ $$aPresas-Rodríguez, Silvia
000131845 700__ $$aGarcía Rubio, Sebatián
000131845 700__ $$aPardiñas Baron, Beatriz$$uUniversidad de Zaragoza
000131845 700__ $$aRamió-Torrentà, Lluís
000131845 700__ $$aSotoca, Javier
000131845 700__ $$aGonzález-Suárez, Inés
000131845 700__ $$aEichau, Sara
000131845 700__ $$aPrieto-González, José M.
000131845 700__ $$aBlasco Quilez, Maria Rosario
000131845 700__ $$aSabín-Muñoz, Julia
000131845 700__ $$aSánchez-López, Antonio José
000131845 700__ $$aLlorens Calatayud, Gloria
000131845 700__ $$aCalles, Carmen
000131845 700__ $$aSempere, Ángel Pérez
000131845 700__ $$0(orcid)0000-0002-1756-5492$$aGarcés, Moises$$uUniversidad de Zaragoza
000131845 700__ $$aCarmona, Olga
000131845 700__ $$aMoral, Ester
000131845 700__ $$aHervás, José Vicente
000131845 700__ $$aBlanco, Yolanda
000131845 700__ $$aSola-Valls, Nuria
000131845 700__ $$aTellez Lara, Nieves
000131845 700__ $$aForero, Lucía
000131845 700__ $$aBrieva, Luis
000131845 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000131845 773__ $$g12, 23 (2023), 7243 [13 pp.]$$pJ. clin.med.$$tJournal of Clinical Medicine$$x2077-0383
000131845 8564_ $$s2540774$$uhttps://zaguan.unizar.es/record/131845/files/texto_completo.pdf$$yVersión publicada
000131845 8564_ $$s2942725$$uhttps://zaguan.unizar.es/record/131845/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000131845 909CO $$ooai:zaguan.unizar.es:131845$$particulos$$pdriver
000131845 951__ $$a2024-11-22-12:10:42
000131845 980__ $$aARTICLE